{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:46:58Z","timestamp":1793321218466,"version":"4.5.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Takeda Pharmaceuticals International AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The development of an in vitro cultivation system for human noroviruses allows the measurement of neutralizing antibody levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Serum neutralizing antibody levels were determined using a GII.4\/Sydney\/2012-like virus in human intestinal enteroids in samples collected before and 4 weeks after administration of an investigational norovirus vaccine and were compared with those measured in histo-blood group antigen (HBGA)\u2013blocking assays.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Neutralizing antibody seroresponses were observed in 71% of 24 vaccinated adults, and antibody levels were highly correlated (r = 0.82, P &lt; .001) with those measured by HBGA blocking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>HBGA-blocking antibodies are a surrogate for neutralization in human noroviruses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT02475278.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiz526","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T15:27:52Z","timestamp":1570634872000},"source":"Crossref","is-referenced-by-count":24,"title":["Comparison of Microneutralization and Histo-Blood Group Antigen\u2013Blocking Assays for Functional Norovirus Antibody Detection"],"prefix":"10.1093","author":[{"given":"Robert L","family":"Atmar","sequence":"first","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Ettayebi","sequence":"additional","affiliation":[{"name":"Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B Vijayalakshmi","family":"Ayyar","sequence":"additional","affiliation":[{"name":"Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick H","family":"Neill","sequence":"additional","affiliation":[{"name":"Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph P","family":"Braun","sequence":"additional","affiliation":[{"name":"Takeda Vaccines Business Unit, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasirekha","family":"Ramani","sequence":"additional","affiliation":[{"name":"Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K","family":"Estes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"2019110219360896100_CIT0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.idc.2017.11.004","article-title":"Norovirus illnesses in children and adolescents","volume":"32","author":"Shah","year":"2018","journal-title":"Infect Dis Clin North Am"},{"key":"2019110219360896100_CIT0002","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.clinthera.2017.07.002","article-title":"Prospects and challenges in the development of a norovirus vaccine","volume":"39","author":"Cortes-Penfield","year":"2017","journal-title":"Clin Ther"},{"key":"2019110219360896100_CIT0003","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1086\/656364","article-title":"Serological correlate of protection against norovirus-induced gastroenteritis","volume":"202","author":"Reeck","year":"2010","journal-title":"J Infect Dis"},{"key":"2019110219360896100_CIT0004","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa1101245","article-title":"Norovirus vaccine against experimental human Norwalk virus illness","volume":"365","author":"Atmar","year":"2011","journal-title":"N Engl J Med"},{"key":"2019110219360896100_CIT0005","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/CVI.00196-15","article-title":"Serological correlates of protection against a GII.4 norovirus","volume":"22","author":"Atmar","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"2019110219360896100_CIT0006","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1126\/science.aaf5211","article-title":"Replication of human noroviruses in stem cell-derived human enteroids","volume":"353","author":"Ettayebi","year":"2016","journal-title":"Science"},{"key":"2019110219360896100_CIT0007","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2018.08.039","article-title":"Human monoclonal antibodies that neutralize pandemic GII.4 noroviruses","volume":"155","author":"Alvarado","year":"2018","journal-title":"Gastroenterology"},{"key":"2019110219360896100_CIT0008","doi-asserted-by":"publisher","DOI":"10.3390\/v11050392","article-title":"In depth breadth analyses of human blockade responses to norovirus and response to vaccination","volume":"11","author":"Haynes","year":"2019","journal-title":"Viruses"},{"key":"2019110219360896100_CIT0009","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1016\/j.vaccine.2012.03.050","article-title":"Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations","volume":"30","author":"Parra","year":"2012","journal-title":"Vaccine"},{"key":"2019110219360896100_CIT0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/infdis\/jiy529","article-title":"An exploratory study of the salivary immunoglobulin a responses to 1 dose of a norovirus virus-like particle candidate vaccine in healthy adults","volume":"219","author":"Atmar","year":"2019","journal-title":"J Infect Dis"},{"key":"2019110219360896100_CIT0011","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/infdis\/jiw259","article-title":"Rapid responses to 2 virus-like particle norovirus vaccine candidate formulations in healthy adults: a randomized controlled trial","volume":"214","author":"Atmar","year":"2016","journal-title":"J Infect Dis"},{"key":"2019110219360896100_CIT0012","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/7651_2017_1","article-title":"Human intestinal enteroids: new models to study gastrointestinal virus infections","volume":"1576","author":"Zou","year":"2019","journal-title":"Methods Mol Biol"},{"key":"2019110219360896100_CIT0013","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","article-title":"Determination of 50% endpoint titer using a simple formula","volume":"5","author":"Ramakrishnan","year":"2016","journal-title":"World J Virol"},{"key":"2019110219360896100_CIT0014","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.immuni.2019.05.007","article-title":"Sera antibody repertoire analyses reveal mechanisms of broad and pandemic strain neutralizing responses after human norovirus vaccination","volume":"50","author":"Lindesmith","year":"2019","journal-title":"Immunity"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz526\/30342569\/jiz526.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz526\/30342569\/jiz526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T19:36:19Z","timestamp":1572723379000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiz526\/5587714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":14,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz526","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"article-number":"jiz526"}}